| Literature DB >> 34519018 |
Ana Macchia1,2, Paul Theo Zebhauser3,4, Stephanie Salcedo5, Bethany Burum5, Edward Gold6, Miguel Alonso-Alonso6, Alvaro Pascual-Leone7,8,9, Daniel Gilbert5, Anna-Katharine Brem10,11,12,13.
Abstract
The neuropeptide oxytocin (OT) has been associated with a broad range of human behaviors, particularly in the domain of social cognition, and is being discussed to play a role in a range of psychiatric disorders. Studies using the Reading The Mind In The Eyes Test (RMET) to investigate the role of OT in mental state recognition reported inconsistent outcomes. The present study applied a randomized, double-blind, cross-over design, and included measures of serum OT. Twenty healthy males received intranasal placebo or OT (24 IU) before performing the RMET. Frequentist and Bayesian analyses showed that contrary to previous studies (Domes et al., 2007; Radke & de Bruijn, 2015), individuals performed worse in the OT condition compared to the placebo condition (p = 0.023, Cohen's d = 0.55, 95% confidence interval [CI] [0.08, 1.02], BF10 = 6.93). OT effects did not depend on item characteristics (difficulty, valence, intensity, sex) of the RMET. Furthermore, OT serum levels did not change after intranasal OT administration. Given that similar study designs lead to heterogeneous outcomes, our results highlight the complexity of OT effects and support evidence that OT might even interfere with social cognitive abilities. However, the Bayesian analysis approach shows that there is only moderate evidence that OT influences mind-reading, highlighting the need for larger-scale studies considering the discussed aspects that might have led to divergent study results.Entities:
Keywords: Oxytocin; RMET; Social cognition; Theory of mind
Mesh:
Substances:
Year: 2021 PMID: 34519018 PMCID: PMC8791897 DOI: 10.3758/s13415-021-00936-3
Source DB: PubMed Journal: Cogn Affect Behav Neurosci ISSN: 1530-7026 Impact factor: 3.282
Characteristics of the current sample and study design compared to previous studies
| Current | Radke & de Bruijn ( | Domes et al. ( | |
|---|---|---|---|
| Sample (final analysis) | 20 healthy males | 24 healthy males | 30 healthy males |
| Mean age, yr (SD) | 22.85 (±3.5) | 21.5 (±1.9) | 25.3 (±2.2) |
| OT dose and visit interval | 24IU, 1 week (administration order randomized) | 24IU, 2 weeks (administration order randomized) | 24IU, 1 week administration order balanced) |
| RMET start (min after OT administration) | 45 | 50 or 65 (counterbalanced) | 45 |
| Activities during waiting period (min after administration) | Watching movie with nature scenes | Answering questionnaires; free to read/study/other occupations | Reading news magazines |
| Country | US | Netherlands | Germany |
| Exclusion criteria | Psychiatric disease; unstable medical condition; smoking; nasal pathologies; drug/alcohol abuse (current abuse or in the past 6 months) | Age <18 or >30 yr; neurological/ endocrine disease; medication use; smoking >5 cigarettes/day; participation in pharmacological study within 2 months before inclusion; sickness on test day (fever, cold, allergic rhinitis) | Medical/psychiatric disease; medication use; smoking; substance abuse |
| Abstinence | Food: 9 h Drink (except water): 2 h Alcohol/caffeine: 24 h Nicotine: exclusion criteria | Food: 2 h Drink (except water): 2 h Alcohol/caffeine: 24 h Nicotine: 24 h | Food: 2 h Drink (except water): 2 h Alcohol/caffeine: 2 h Nicotine: 2 h |
| Recruitment | Advertisement on university campus and online postings | Advertisement on university campus and online recruitment system | Advertisement on university campus |
| Questionnaires | EQ IRI MDMQ BIS | EQ IRI VAS STAXI SAS | MDMQ |
| Incentive | Financial compensation (50$) | Financial compensation (50€) | None |
BIS, Barratt Impulsiveness Scale; EQ, Empathy Quotient; IRI, Interpersonal Reactivity Index; MDMQ, Multidimensional Mood Questionnaire; RMET, Reading the Mind in the Eyes Test; STAXI, State-Trait Anxiety Inventory; SAS, Social Anxiety Scale; VAS, visual analogue scale for nonspecific effects of OT.
Fig. 1Detailed study procedure for each visit. After giving written, informed consent, the IV was inserted and three baseline blood samples (pre) were collected, spaced 5 min apart. Participants randomly received intranasal PLC or OT. While waiting 45 min for the OT effect to fully emerge (Spengler et al., 2017), individuals watched a distractor movie showing nature scenes. During the waiting period, subjects were left alone and were not allowed to use a mobile phone to minimize human interaction. After the waiting period, a fourth blood sample (post) was drawn. Then, the RMET and the Multidimensional Mood Questionnaire (MDMQ) (Steyer et al., 1994) were performed. Other questionnaires were administered via an online tool. Both the OT and the PLC visit followed the same procedure.
Summary of statistics and descriptive for previous studies
| Current | Radke et al. ( | Domes et al. ( | |
|---|---|---|---|
| OT vs. PLC | OT vs. PLC | OT vs. PLC | |
| RMET in % | |||
72.92 (7.9) vs. 78.06 (7.1) d = 0.55, 95% CI [0.08, 1.02] | 68.9 (12.6) vs.67.8 (12.6) d = 0.09, 95% CI [-0.31, 0.49] | 72.4 (8.6) vs. 69.4 (8.1) d = 0.40, 95% CI [−0.77, 0.02] | |
| BF10 (BF01) | Informed prior: 6.93 (0.14); Mdn = 0.34; 95% CI [0.13, 0.75] Oosterwijk prior: 9.70 (0.10); Mdn = 0.39; 95% CI [0.18, 0.66] | Informed prior: 0.60 (1.66); Mdn = 0.24; 95% CI [−0.09, 0.44] Oosterwijk prior: 0.534 (1.87); Mdn = 0.29; 95% CI [0.01, 0.48] | Informed prior: 3.29 (0.30); Mdn = −0.30; 95% CI [−0.68, −0.02] Oosterwijk prior: 3.52 (0.28); Mdn = −0.22; 95% CI, [−0.60, −0.01] |
| RMET item classification in % | |||
| Easy vs. difficult | 81.5 (±8.8) vs. 69.4 (±12.8) | 73.6 (±2.5) vs. 63.1 (±2.6) | |
| Positive vs. negative | 78.8 (±11.5) vs. 73.2 (±11.4) | 72.8 (±3.0) vs. 63.4 (±2.4) | |
| High vs. low | 80.4 (±8.7) vs. 70.6 (±11.4) | 74.3 (±2.2) vs. 62.4 (±2.8) | |
| Female vs. male | 78.4 (±10.0) vs. 72.9 (±10.0) | 68.6 (±2.6) vs. 68.0 (±2.6) | |
| MDMQ | |||
| Arousal | 33.9 (±4.7) vs. 34.6 (±3.5) | 34.3 (±4.7) vs. 34.0 (±4.8) | |
| Wakefulness | 35.8 (±2.8) vs. 33.9 (±4.3) | 28.8 (±6.8) vs. 28.2 (±7.1) | |
| Mood | 30.8 (±3.3) vs. 31.4 (±3.1) | 35.6 (±4.1) vs. 34.2 (±4.5) | |
| Questionnaires | |||
| EQ | 37.2 (±7.6) | 33.8 (±10.8) | |
| IRI-PT | 23.1 (±3.1) | 22.7 (±5.2) | |
| IRI-EC | 22.6 (±2.0) | 21.9 (±2.8) | |
| IRI-F | 22.2 (±4.6) | 22.5 (±4.8) | |
| IRI-PD | 18.4 (±3.2) | 16.8 (±4.3) | |
| BIS-total | 63.0 (±9.0) | ||
| BIS-attentional | 16.9 (±3.2) | ||
| BIS-motor | 23.1 (±3.7) | ||
| BIS-nonplanning | 23.0 (±4.7) | ||
Means with standard deviations except for t-test results. Effect size d according to Cohen (Cohen, 1988): small effect d = 0.2, medium effect d = 0.50, large effect d = 0.80. BF10: Bayes factor to quantify evidence for the alternative hypothesis relative to the null hypothesis; BF01: Bayes factor to quantify evidence for the null hypothesis relative to the alternative hypothesis; Mdn = median effect size and 95% credible intervals of the posterior distribution of the effect size; BIS, Barratt Impulsiveness scale; EQ, empathy quotient; IRI, Interpersonal Reactivity Index; IRI-PT, IRI perspective taking; IRI-EC, IRI empathic concern; IRI-F, IRI fantasy; IRI-PD, IRI personal distress; MDMQ, Multidimensional Mood Questionnaire; N.A., not available; OT, oxytocin; PLC, placebo; RMET, Reading the Mind in the Eyes Test.
Fig. 2Total RMET scores in the OT and PLC conditions. Boxplots (top) and Density distributions (bottom) indicate that participants receiving OT performed worse in the RMET. Density plots show that RMET scores in the OT condition are concentrated on a lower interval compared with the PLC condition
Fig. 3Correlation of the RMET score and perspective taking (IRI-PT). Scatterplot with regression lines for the RMET score in the PLC (red dots, solid line) and the OT (blue dots, dotted line) condition and their relation to the perspective taking scale of the IRI (IRI-PT). In the OT but not the PLC condition, the RMET score was negatively correlated with perspective taking. Note that one participant did not answer the online questionnaires.